NeuroOne MedicalNMTC.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, NeuroOne Medical (NMTC.O) trades at a negative P/E (-1.18x, due to a recent net loss), P/B of 2.33x, P/S of 1.35x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 13th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 51st percentile within its industry and the 63rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.42%, ranking at the 100th percentile over the trailing 20Y window.
The P/B percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here lean heavily on buybacks rather than cash dividends. NeuroOne Medical operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: NMTC · NMTC
Want the full picture on whether NeuroOne Medical (NMTC.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -1.18 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 2.33 | ||||||
| P/S (TTM) | 1.35 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 1.42% |